Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
Cardiovascular Diabetology, 2019 Sotagliflozin is a dual sodium–glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium–glucose co-transporter 2 (determining significant excretion of glucose
Chiara Maria Assunta Cefalo +7 more
doaj +1 more source
FEBS Open Bio, 2014 The di-peptide Trp-His (WH) has vasorelaxant and anti-atherosclerotic functions. We hypothesized that WH has multiple biological functions and may aid AMP-activated protein kinase (AMPK) activation and affect the glucose transport system in skeletal ...
Minoru Soga +4 more
doaj +1 more source
Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine [PDF]
, 2019 Type 2 diabetes mellitus (T2DM) is a chronic disease that has reached the levels of a global epidemic. In order to achieve optimal glucose control, it is often necessary to rely on combination therapy of multiple drugs or insulin because uncontrolled ...
Andreozzi, F, Mannino, Gc, Sesti, G
core +1 more source
Neurological Sciences and Neurophysiology, 2022 Glucose transporter type 1 deficiency syndrome (GLUT-1 DS) is an inborn error of metabolism that results in defective glucose transport and consequently a reduced supply of glucose to the brain.
Zuhal Yapici +4 more
doaj +1 more source
The effects of empagliflozin in patients with type 1 diabetes: Results of a 12-week, double-blind, randomized, placebo-controlled clinical trial [PDF]
Health Promotion PerspectivesBackground: Sodium-glucose cotransporter-2 (SGLT-2) acts as a key element in the reabsorption of glucose in the kidney. Currently, SGLT-2 inhibitors are FDA-approved for the treatment of type 2 diabetes.
Mostafa Najafipour +6 more
doaj +1 more source
Proton-coupled sugar transport in the prototypical major facilitator superfamily protein XylE. [PDF]
, 2014 The major facilitator superfamily (MFS) is the largest collection of structurally related membrane proteins that transport a wide array of substrates.
Gonen, Tamir +4 more
core +3 more sources
Long-Term Effect of GPi-DBS in a Patient With Generalized Dystonia Due to GLUT1 Deficiency Syndrome
Frontiers in Neurology, 2018 Treatment outcomes from pallidal deep brain stimulation are highly heterogeneous reflecting the phenotypic and etiologic spectrum of dystonia. Treatment stratification to neurostimulation therapy primarily relies on the phenotypic motor presentation ...
Idil Hanci +23 more
doaj +1 more source
Use of modified Atkins diet in glucose transporter type 1 deficiency syndrome [PDF]
Developmental Medicine & Child Neurology, 2016 AimGlucose transporter type 1 deficiency syndrome (GLUT1‐DS) results from impaired glucose transport into the brain, and is treated with a ketogenic diet. A few reports have suggested effectiveness of treatment using the modified Atkins diet (MAD). We aimed to assess the efficacy of MAD as a treatment for GLUT1‐DS.MethodWe evaluated the efficacy of MAD
Stéphane Auvin +7 more
openaire +3 more sources
Dietary l-Arginine Supplementation Protects Weanling Pigs from Deoxynivalenol-Induced Toxicity
Toxins, 2015 This study was conducted to determine the positive effects of dietary supplementation with l-arginine (Arg) on piglets fed a deoxynivalenol (DON)-contaminated diet.
Li Wu +8 more
doaj +1 more source
Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes [PDF]
, 2017 Background: Sodium glucose co-transporter 2 (SGLT2) inhibitors may reduce cardiovascular and heart failure risk in patients with type 2 diabetes mellitus (T2DM).
Butler, Javed +6 more
core +1 more source